

Product Name: PSI Revision Date: 01/10/2021 Product Data Sheet

> 0 H

PSI

		22
Cat. No.:	A1900	of b
CAS No.:	1 <mark>584</mark> 42-41-2	P1,
Formula:	C32H50N4O8	HN
M.Wt:	618.76	ONHO
Synonyms:	Z-Ile-Glu(OtBu)-Ala-Leu-CHO	J' HN
Target:	Ubiquitination/ Proteasome	OT OT NH
Pathway:	Proteasome	XĽ
Storage:	Store at -20°C	
	810	BIO

Solvent & Solubility

	\geq 30.6 mg/mL in DMSO; insoluble in H2O; \geq 48.7 mg/mL in EtOH				
In Vitro	Preparing Stock Solutions	Mass Solvent Concentration	1mg	5mg	10mg
		1 mM	1.6161 mL	8.0807 mL	16.1614 mL
		5 mM	0.3232 mL	1.6161 mL	3.2323 mL
		10 mM	0.1616 mL	0.8081 mL	1.6161 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

Proteasome inhibitor

IC₅₀ & Target

In Vitro

Part of the second s		
STAV-AB and STAV-FCS cells		
The solubility of this compound in DMSO is >10 mM. General tips for obtaining		
a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or		
shake it in the ultrasonic bath for a while.Stock solution can be stored below		
-20°C for several months.		
IC50: 4.01µM for STAV-AB, 24 hours 16.31µM for STAV-FCS, 24 hours		

1 | www.apexbt.com

	Applications:	Treatment with PSI reduced the viability of the two MM cell sub-lines to different			
		extents in a time and concentration-dependent manner. Thus exposure to PSI			
		for 24 h resulted in an IC50of 4.01 μ M on STAV-AB cells, but 16.31 μ M of the			
		same drug was needed for a similar reduction in cell numbers on STAV-FCS			
		cells.			
	Animal experiment	610			
In Vivo	Animal models:	Male Sprague-Dawley adult rats			
	Dosage form:	Subcutaneous injection, 6.0 mg/kg			
	Applications:	The effects of PSI treatment on the amount of dopamine and the dopamin			
		metabolite DOPAC in the striata, were evaluated by HPLC analysis. Decreased			
		levels of DA in the striatum were found at 6 weeks after the end of PSI			
		treatment as compared to controls; a decrement was also observed in the level			
		of DOPAC in the PSI-treated rats, but did not reach statistical significance.			
		DOPAC/DA ratio was unchanged in the PSI-treated rats as compared to			
	310	controls, highlighting that reduction of DA level in the striatum of PSI treated			
	of the second second	rats was not attributable to increased DA metabolism.			
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may			
		slightly differ with the theoretical value. This is caused by an experimental			
		system error and it is normal.			

Product Citations

See more customer validations on www.apexbt.com.

References

[1] Sun X, Gulyás M, Hjerpe A, et al. Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer letters, 2006, 232(2): 161-169.

[2] Pizzi S D, Rossi C, Di Matteo V, et al. Morphological and metabolic changes in the nigro-striatal pathway of synthetic proteasome inhibitor (PSI)-treated rats: a MRI and MRS study. PloS one, 2013, 8(2): e56501.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for **2** | www.apexbt.com

long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com





APEEBI







